Your Messages Inbox
Your Article Summary
See Latest ArticlesCell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
Cell Therapeutics, 08/24/09
Cell Therapeutics, Inc. announced the closing of its previously announced sale of $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. The investor has elected to convert all of its shares of Series 2 Preferred Stock and to receive the 18,853,103 shares of the Company's common stock issuable upon such conversion at the closing.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Go Go Generics
PharmExec, 12/18/09
Almirall and Forest Laboratories to Expand Respiratory Collaboration with LAS100977
Forest Laboratories, 12/18/09
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Article Search
Sponsor